BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 2460018)

  • 1. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of tumor markers in prostatic cancer].
    Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
    Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
    Mortarelli EA
    Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
    Shinoda I
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
    Moul JW; Connelly RR; Perahia B; McLeod DG
    J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
    Barak M; Mecz Y; Lurie A; Gruener N
    J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoma of the prostate. Serum tumour markers.
    Ekman P
    Scand J Urol Nephrol Suppl; 1991; 139():15-8. PubMed ID: 1722588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F; Zambolin T; Bonora R; Panteghini M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
    Kabalin JN
    Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.